NCT02892916View on ClinicalTrials.gov

Ketamine and Postoperative Cognitive Dysfunction

PHASE3CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Post Operative Cognitive Dysfunction
Interventions
DRUG

Ketamine

A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.

DRUG

Placebo

A bolus of an intravenous normal saline solution following induction of anaesthesia.

Trial Locations (1)

75012

AP-HP - Hôpital Saint-Antoine, Paris

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02892916 - Ketamine and Postoperative Cognitive Dysfunction | Biotech Hunter | Biotech Hunter